This segment focuses on the research, development, and manufacturing of recombinant protein drugs using advanced genetic engineering technologies. The company's R&D activities include optimizing protein expression, purification, and formulation to enhance drug efficacy and stability. Key therapeutic areas include hematology, oncology, and infectious diseases. Amoytop leverages its expertise in recombinant protein technology to develop biosimilars and novel biologics, addressing unmet medical needs and improving patient outcomes. The company's market positioning is strengthened by its robust manufacturing capabilities and strategic partnerships, enabling it to compete effectively in the biopharmaceutical market. Future opportunities include expanding its product pipeline and entering new therapeutic areas.

This segment is dedicated to the research and development of innovative treatments for hepatitis and related conditions, including hepatocellular carcinoma. Amoytop Biotech is actively involved in clinical trials and collaborations to advance its pipeline of therapeutic candidates. The company's research focuses on cytokines and innate immunity agonists, aiming to develop first-in-class treatments that can improve patient outcomes. By partnering with companies like Drug Farm and Aligos Therapeutics, Amoytop is expanding its capabilities and market reach in this critical therapeutic area. The company's commitment to innovation and collaboration positions it as a key player in the fight against hepatitis and liver cancer.